1 / 34

MALARIA VACCINES A tale of two vaccines (and more)

MALARIA VACCINES A tale of two vaccines (and more). Brian Greenwood LSHTM. 40 th Anniversary Tropical Epidemiology Unit March 29 th – 30 th , 2012. WHY WE NEED A MALARIA VACCINE. Malaria has not been controlled by widespread deployment

shina
Télécharger la présentation

MALARIA VACCINES A tale of two vaccines (and more)

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. MALARIA VACCINES A tale of two vaccines (and more) Brian Greenwood LSHTM 40th Anniversary Tropical Epidemiology Unit March 29th – 30th, 2012

  2. WHY WE NEED A MALARIA VACCINE • Malaria has not been controlled by widespread deployment • of existing control tools in many endemic areas. • There is increasing concern about the emergence of • resistance to insecticides and antimalarial drugs. • Vaccination is a relatively easy tool to deliver. • Vaccination has played a key role in previous elimination/ • eradication programmes – smallpox, rinderpest, (polio).

  3. WHAT WE EXPECT FROM A MALARIA VACCINE • Provision of direct, individual protection against • malaria infection and its clinical consequences. • Reduction in transmission of malaria infection • (herd immunity).

  4. TYPES OF MALARIA VACCINES Pre-erythrocytic vaccines Vaccines that block transmission Blood-stage vaccines

  5. MALARIA VACCINE DEVELOPMENT • Prevention of malaria in canaries using attenuated sporozoites. • 1960s Vaccination of mice with irradiated sporozoites and discovery of • circumsporozoite protein (CSP). • Prevention of malaria in human volunteers using irradiated sporozoites. • 1990s Clinical trials of the blood stage peptide vaccine SPf66. • 2000s Demonstration of the efficacy of RTS,S in volunteers. • First trials of DNA vaccines. • Development of the prime boost approach using viral vectors. • 2010 - Phase 3 trial of RTSS. • About 30 new vaccines in clinical development.

  6. THE SPf66 VACCINE Dr Manuel Patarroyo

  7. DEVELOPMENT OF THE SPf66 VACCINE • A large number of synthetic • peptides made. • Peptides screened in a • monkey model. • The three peptides giving the • best protection combined to • make SPf66.

  8. TRIALS OF SPf66 IN SOUTH AMERICA Country Age group Subjects Number PE (95% CI) of cases % Spf66 Control Spf66 Control Brazil7- 60 yrs 287 285 107 107 -2 (-32 to 22) Colombia Adults 185 214 2 9 83 Colombia > I year 643 623 53 81 35 (8 to 54) Colombia > 1 year 738 810 168 297 34 (19 to 46)* Ecuador > 1 year 230 238 4 12 67 (3 to 89) Venezuela7- 60 yrs 287 285 102 184 55 (21 to 75)

  9. GETTING THE VACCINE TO AFRICA • Delegations to Colombia. • Visit of Dr Patarroyo to The Gambia. • Dr Patarroyo agreed to donate vaccine • for a trial in Africa. • WHO approval for a trial in Africa. • Opposition of MRC to a Gambian trial. • Trial undertaken in Tanzania.

  10. TRIALS OF SPf66 IN AFRICA AND ASIA Country Age group Subjects Number PE (95% CI) of cases % Spf66 Control Spf66 Control Tanzania 1 - 5 yrs 274 312 73 102 32 (0 to 52) Tanzania < 1 yr (EPI) 550 541 541 547 2 (-16 to 16) Gambia 6 - 11 months 316 231 160 121 8 (-18 to 29) Thailand 2 - 15 yrs 680 668 195 184 - 9 (-33 to 14)

  11. LESSONS LEARNT FROM SPf66 • Malaria vaccine trials require vigorous study design. • Efficacy may be influenced by local epidemiology. • Without an understanding of the mode of action of • a vaccine, unravelling conflicting results is difficult. • Vaccines developed outside the ‘conventional’ system • will be controversial. • The SPf66 trials helped in the design of future malaria • trials and their end-points. • The SPf66 trials provided a key learning experience • for the first generation of malaria field vaccinologists.

  12. CSP VACCINES The Circumsporozoite Protein (CSP) Prof. Ruth Nussensweig

  13. + S HBsAg RTS,S RTS,S The circumsporozoite protein SS RI Repeat NANPRII GPI Target of neutralizing antibodies T cell epitopes R T S HBsAg + Adjuvant (Gordon et al. J Infect Dis1995;171:1576–85)

  14. CHALLENGE STUDY IN AMERICAN VOLUNTEERS Malaria on challenge Control group 6/6 RTS,S + alum + monophosphoryl A 7/8 RTS,S in an oil-in-water emulsion 5/7 RTS,S in an oil-in-water emulsion 1/7 + monophosphoryl A + QS21 (Stoute et al. NEJM 1997;336;86-91)

  15. A TRIAL OF RTS,S/AS02 IN GAMBIAN ADULTS Probability of remaining free of parasitaemia Weeks of surveillance (Bojang et al. Lancet 2001;358:1927-34)

  16. DURATION OF PROTECTION IN GAMBIAN ADULTS % Protection against malaria Overall First 9 weeks Next 6 weeks Following re-vaccination Time after vaccination (Bojang et al., Lancet 2001; 358:1927-34)

  17. RTS,S/ASO2 IN MOZAMBICAN CHILDREN Vaccine Efficacy (VE) Clinical malaria 29.9% (11.0-44.8%) Severe malaria 57.7% (16.2-80,6%) 6 months (Alonso et al Lancet 2004 364:1411-20)

  18. DURATION OF PROTECTION IN MOZAMBICAN CHILDREN Vaccine Efficacy (VE) Clinical malaria – all episodes 25.6 % (11.9,37.1%) 42 months (Sacaral et al. JID 2009; 200:329-36) (Sacaral et al. JID 2009:200:329-36)

  19. A BETTER ADJUVANT - AS01 A trial in Kenyan children Vaccine Efficacy (VE) Clinical malaria 56% (31.0-72%) (Bejon et al. NEJM 2008:359:2521-32)

  20. THE PHASE 3 RTS,S/AS01 TRIAL Design Study groups: children 5 - 17 months (RTS,S separate from EPI vaccines)(6,000) infants 2 - 4 months (RTS,S given with EPI vaccines)(6,000)

  21. THE PHASE 3 RTS,S/AS01 TRIAL Study centres 7 countries 11 centres

  22. TRIAL END-POINTS • Primary • Efficacy against clinical malaria 12 months after vaccination in the • 5 -17 month group. • Efficacy against clinical malaria 12 months after vaccination in the • 6 - 12 week group. • Secondary • Efficacy against severe malaria, anaemia and hospital admissions. • Efficacy against malaria 30 months after completion ofvaccination. • Efficacy against malaria infection and impact on parasite population. • Efficacy of a booster immunisation. • The effect of the level of transmission on efficacy. • Immunogenicity. • Safety.

  23. THE PHASE 3 RTS,S/AS01 TRIAL Efficacy after 12 months in the 5-17 month group 6,000 children Uncomplicated malaria VE = 50.4% (48.5-54.6%) Severe malaria VE = 45.1% (23.8-60.5%) (RTS,S Clinical Trials partnership NEJM 2011;365:1863-75.)

  24. RTS,S/ASO1 PHASE 3 TRIAL Next steps • 2012Analysis of efficacy in infants at 12 months. • 2013/14 Analysis of - duration of protection. • - impact by level of transmission. • - impact on additional end-points. • 2014/15 Potential licensure. • 2015 Possible deployment in routine immunisation • programmes (Phase 4 programmes). Where and how should RTS,S/AS01 be used if licensed?

  25. SECOND GENERATION VACCINES Malaria Road Map Target for 2025 - 80% protection against clinical malaria - persistence of protection for 4 years Achieving the Target - vaccines that are more efficacious than RTS,S/AS01 - combination vaccines - stages of the lifecycle - different proteins

  26. TYPES OF MALARIA VACCINES Pre-erythrocytic vaccines Vaccines that block transmission Blood-stage vaccines

  27. PRE-ERYTHROCYTIC VACCINES Second generation • Irradiated sporozoites (PfSPZ)(Sanaria) • Produced to GMP standards. • May need to be given intravenously. • Need to be stored in liquid nitrogen. • Would be expected to give a high level of protection. • Challenge and treatment • Two years of protection following inoculation • whilst receiving chloroquine treatment. • Viral vectored vaccines • Pox viruses and adenoviruses (human and chimp). • Work best using the ‘prime boost’ strategy. • Induce strong T cell responses. • Some protection seen in challenge studies.

  28. BLOOD STAGE VACCINES Second generation • MSP1 - First malaria blood stage antigen to be investigated. • - Many constructs have failed to give protection. • AMA1 -Involved in red cell invasion – very variable antigen. • - Some protection found against one variant in Mali trial. • - AMA1 virosome + CSP gave protection in Tanzania. • MSP 3- Induces a specific kind of immune response. • - Protection achieved in one pilot study in Burkina Faso. • GMZ2 - A combination of MSP3 and GLURP. • - A large multicentre trial currently underway in Africa. • SE36 - Based on the blood stage antigen SERA. • - Gave protection in children in Uganda.

  29. TRANSMISSION BLOCKING VACCINES • Pf s25 -Immune response directed at the parasite in in the mosquito. • - Little antigenic variability. • - No boosting. • Pvs 25 - Related antigen in Plasmodium vivax. • - In clinical trials. • Pf45/48 - Antibody directed at the gametocytes. • - Has been very difficult to produce in an immunogenic form. • - Some success with conjugation to EPA. • AnAPN1 - Attacks the mosquito midgut. • - Could provide cross-species protection. Membrane feeding assay

  30. VACCINES FOR ELIMINATION (MalERA consultative group on vaccines. PloS Med 2011;8:e1000398)

  31. WHO RAINBOW CHART WHO.int/entity/vaccine_research/documents/rainbow_table 28

  32. CHALLENGES FOR SECOND GENERATION MALARIA VACCINES • Trial design - need to compare with RTS,S ? • - inferiority or superiority? • - how to test combinations? • Transmission blocking vaccines • - need for community randomised trials? • - ethics of randomised trials ? • - licensure on immunogencity?

  33. SUMMARY • Malaria control is threatened by resistance to artemisinins • and pyrethroids and so malaria vaccines will be needed for • control in some areas and probably for elimination. • Many more candidate malaria vaccines will reach the stage of • clinical trials in endemic areas in the next decade. • Evaluation of second generation vaccines will be challenging • and expensive. • Substantial funds will be needed to ensure deployment of • malaria vaccines once they have been licensed.

  34. Dr Owusu and the first child to receive RTS,S/AS01, Kintampo, Ghana

More Related